{"id":"NCT01125566","sponsor":"Boehringer Ingelheim","briefTitle":"LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment","officialTitle":"LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06-22","primaryCompletion":"2013-06-08","completion":"2018-07-06","firstPosted":"2010-05-18","resultsPosted":"2014-08-21","lastUpdate":"2019-07-18"},"enrollment":508,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"BIBW 2992","otherNames":[]},{"type":"DRUG","name":"trastuzumab","otherNames":[]},{"type":"DRUG","name":"vinorelbine","otherNames":[]},{"type":"DRUG","name":"vinorelbine","otherNames":[]}],"arms":[{"label":"Arm B: trastuzumab with vinorelbine","type":"ACTIVE_COMPARATOR"},{"label":"Arm A: BIBW 2992 with vinorelbine","type":"EXPERIMENTAL"}],"summary":"To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (Herceptin®) treatment","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"From randomization (07Sep2010) until disease progression, death or data cut-off (08Jun2013); Up to 34 months","effectByArm":[{"arm":"Afatinib + Vinorelbine (AV)","deltaMin":5.49,"sd":null},{"arm":"Trastuzumab + Vinorelbine (TV)","deltaMin":5.55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4224"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":207,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Brazil","Canada","Chile","China","Czechia","Egypt","France","Germany","India","Ireland","Israel","Italy","Japan","Latvia","Lebanon","Lithuania","Mexico","Netherlands","Peru","Poland","Portugal","Russia","Singapore","Slovakia","Slovenia","South Africa","South Korea","Spain","Sri Lanka","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["26822398"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":123,"n":337},"commonTop":["Neutropenia","Diarrhoea","Leukopenia","Anaemia","Rash"]}}